<DOC>
	<DOCNO>NCT01446133</DOCNO>
	<brief_summary>The goal clinical research study learn combination lenalidomide rituximab help control CLL . The safety drug combination also study . Lenalidomide design change body 's immune system . It may also interfere development tiny blood vessel help support tumor growth . This may decrease growth cancer cell . Rituximab design attach cancer cell damage , may cause cell die .</brief_summary>
	<brief_title>Combination Lenalidomide Rituximab Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma ( CLL-SLL )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , begin take study drug 28-day cycle . One time week Cycle 1 , receive rituximab vein . During Cycle 2 , receive rituximab . During Cycles 3-12 , receive rituximab Day 1 Cycles 3-12 . Your first dose rituximab give 6-8 hour . If tolerate first dose well , may receive next dos 2-4 hour . If doctor think need , next dos may give long time . Starting Day 9 Cycle 1 , begin take lenalidomide mouth 1 time day . The dose schedule lenalidomide may change depend side effect may . You swallow lenalidomide capsule whole glass ( 8 ounce ) water time day . Do break , chew , open capsule . If miss dose lenalidomide , take soon remember day . If miss dose , NOT make another day . During Cycle 1 , take allopurinol mouth 1 time day Days 1-14 low risk side effect . Study Visits : One ( 1 ) time week first 5 week , blood ( 1 tablespoon ) drawn routine test . After first 5 week , blood ( 1 tablespoon ) drawn routine test every 2 week doctor think dose lenalidomide stay . After , blood ( 1 tablespoon ) drawn every 4 week rest study routine test . At end Cycles 3 , 6 , 12 , bone marrow biopsy aspiration check status disease . If stay study past 12 cycle , every 6 cycle ( Cycles 18 , 24 , 30 , ) , bone marrow biopsy aspiration check status disease . Blood ( 1 tablespoon ) drawn often dose lenalidomide need change intolerable side effect . Pregnancy Testing : If able become pregnant , urine blood ( le 1 teaspoon ) pregnancy test 10-14 day 24 hour first dose lenalidomide , even menstrual period due treatment disease 1 menstrual period past 24 month . If regular menstrual cycle , urine blood ( le 1 teaspoon ) pregnancy test every week first 4 week , every 4 week take lenalidomide , soon stop take lenalidomide , 28 day stop take lenalidomide . If irregular menstrual cycle , urine blood ( le 1 teaspoon ) pregnancy test every week first 4 week , every 2 week take lenalidomide , soon stop take lenalidomide , 14 day 28 day stop take lenalidomide . Length Treatment : You may receive rituximab 12 cycle . You may continue take lenalidomide long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete last study drug dose ( male ) last follow-up pregnancy test ( female ) . This investigational study . Lenalidomide rituximab FDA approve commercially available . Lenalidomide approve treatment multiple myeloma myelodysplastic syndrome . Rituximab approve treatment CLL . The combination drug treat CLL investigational . Up 120 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Age &gt; /18 time sign informed consent.Understand voluntarily sign informed consent . 2 . Patients chronic lymphocytic leukemia untreated disease indication treatment candidate unwilling receive chemoimmunotherapy , patient age previously treat CLL/SLL recurrent disease . Patients recurrent disease eligible receive prior treatment purine analog base chemotherapy chemoimmunotherapy bendamustine . 3 . ECOG/WHO performance status 02 . 4 . Adequate renal function indicate serum creatinine less equal 2mg/dL 5 . Adequate hepatic function indicate total bilirubin less equal 2mg/dL ALT less equal 2 time upper limit normal . 6 . Disease free prior malignancy 3 year exception current basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast . Patients malignancy indolent behavior prostate cancer treat radiation surgery enrol study long reasonable expectation cure treatment modality receive . 7 . All study participant must register mandatory RevAssist program willing able comply program requirement . 8 . Females childbearing potential ( FCBP ) must negative serum urine pregnancy test sensitivity least 50 mlU/mL within 1014 day within 24 hour prior prescribe lenalidomide Cycle 1 . Prescriptions must fill within 7 day must either commit continued abstinence heterosexual intercourse use two acceptable method birth control , one highly effective method one additional effective method time least 28 day start take lenalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . 1 . Known sensitivity lenalidomide thalidomide derivative rituximab . 2 . Documented prolymphocytic leukemia ( prolymphocytes 55 % peripheral blood ) . 3 . Known positivity HIV active hepatitis B C. 4 . Pregnant breast feeding female . 5 . History tuberculosis treat within last five year recent exposure tuberculosis . 6 . Any serious medical condition , laboratory abnormality , psychiatric illness place subject unacceptable risk he/she participate study . 7 . Patients recent history deep vein thrombosis ( DVT ) pulmonary embolus ( PE ) six month prior enrollment eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>SLL</keyword>
	<keyword>Initial Treatment</keyword>
	<keyword>Subsequent Therapy</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
</DOC>